1. Home
  2. ACR vs VTYX Comparison

ACR vs VTYX Comparison

Compare ACR & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACR
  • VTYX
  • Stock Information
  • Founded
  • ACR 2005
  • VTYX 2018
  • Country
  • ACR United States
  • VTYX United States
  • Employees
  • ACR N/A
  • VTYX N/A
  • Industry
  • ACR Real Estate Investment Trusts
  • VTYX Medicinal Chemicals and Botanical Products
  • Sector
  • ACR Real Estate
  • VTYX Health Care
  • Exchange
  • ACR Nasdaq
  • VTYX Nasdaq
  • Market Cap
  • ACR 143.3M
  • VTYX 154.9M
  • IPO Year
  • ACR N/A
  • VTYX 2021
  • Fundamental
  • Price
  • ACR $21.04
  • VTYX $10.38
  • Analyst Decision
  • ACR Buy
  • VTYX Strong Buy
  • Analyst Count
  • ACR 2
  • VTYX 5
  • Target Price
  • ACR $24.50
  • VTYX $14.60
  • AVG Volume (30 Days)
  • ACR 41.7K
  • VTYX 2.5M
  • Earning Date
  • ACR 10-29-2025
  • VTYX 11-06-2025
  • Dividend Yield
  • ACR N/A
  • VTYX N/A
  • EPS Growth
  • ACR 14.65
  • VTYX N/A
  • EPS
  • ACR 0.95
  • VTYX N/A
  • Revenue
  • ACR $88,952,000.00
  • VTYX N/A
  • Revenue This Year
  • ACR $7.03
  • VTYX N/A
  • Revenue Next Year
  • ACR $3.26
  • VTYX N/A
  • P/E Ratio
  • ACR $21.66
  • VTYX N/A
  • Revenue Growth
  • ACR 14.87
  • VTYX N/A
  • 52 Week Low
  • ACR $14.94
  • VTYX $0.78
  • 52 Week High
  • ACR $23.81
  • VTYX $10.47
  • Technical
  • Relative Strength Index (RSI)
  • ACR 53.66
  • VTYX 74.09
  • Support Level
  • ACR $19.60
  • VTYX $8.90
  • Resistance Level
  • ACR $21.61
  • VTYX $10.02
  • Average True Range (ATR)
  • ACR 0.53
  • VTYX 0.78
  • MACD
  • ACR -0.09
  • VTYX -0.10
  • Stochastic Oscillator
  • ACR 62.45
  • VTYX 94.86

About ACR ACRES Commercial Realty Corp.

ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralize debt obligations, and private equity investments mainly issued by financial institutions.

About VTYX Ventyx Biosciences Inc.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Share on Social Networks: